

## Highlights of This Issue 6645

### SPECIAL FEATURES

#### CCR Translations

- 6647 | **The Context of Blood Vessels and Response to VEGF-Targeted Therapy**  
Brian I. Rini  
*See related article, p. 6943*

#### CCR Perspectives in Drug Approval

- 6650 | **Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary**  
Paul G. Kluetz, Yang-Min Ning, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Debasis Ghosh, Robeena Aziz, Todd Palmby, Elimika Pfuma, Jeanne Fourie Zirkelbach, Nitin Mehrotra, Amy Tilley, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, and Richard Pazdur

#### CCR Drug Updates

- 6657 | **Pralatrexate Pharmacology and Clinical Development**  
Enrica Marchi, Michael Mangone, Kelly Zullo, and Owen A. O'Connor

#### Molecular Pathways

- 6662 | **Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma**  
Lorena Fontán and Ari Melnick

#### Perspectives

- 6669 | **Anticipating the Clinical Use of Prognostic Gene Expression-Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?**  
Anita Sveen, Arild Nesbakken, Trude H. Ågesen, Marianne G. Guren, Kjell M. Tveit, Rolf I. Skotheim, and Ragnhild A. Lothe

#### Review

- 6678 | **Hepatocellular Carcinoma from an Immunologic Perspective**  
Tim F. Greten, Austin G. Duffy, and Firouzeh Korangy

#### HUMAN CANCER BIOLOGY

- 6686 | **Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies**  
Rita Coutinho, Andrew James Clear, Andrew Owen, Andrew Wilson, Janet Matthews, Abigail Lee, Rute Alvarez, Maria Gomes da Silva, José Cabeçadas, Maria Calaminici, and John G. Gribben

- 6696 | **BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition**

Katherine E. Hutchinson, Doron Lipson, Philip J. Stephens, Geoff Otto, Brian D. Lehmann, Pamela L. Lyle, Cindy L. Vnencak-Jones, Jeffrey S. Ross, Jennifer A. Pietenpol, Jeffrey A. Sosman, Igor Puzanov, Vincent A. Miller, and William Pao

- 6703 | **HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s**

Ling Li, Wenhua Tang, Xiaoqing Wu, David Karnak, Xiaojie Meng, Rachel Thompson, Xinbao Hao, Yongmin Li, Xiaotan T. Qiao, Jiayuh Lin, James Fuchs, Diane M. Simeone, Zhi-Nan Chen, Theodore S. Lawrence, and Liang Xu

#### CANCER THERAPY: PRECLINICAL

- 6716 | **Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an *In Vivo* Model of Childhood Astrocytoma**  
Hemant K. Bid, Aaron Kibler, Doris A. Phelps, Sagymbek Manap, Linlin Xiao, Jiayuh Lin, David Capper, Duane Oswald, Brian Geier, Mariko DeWire, Paul D. Smith, Raushan T. Kurmasheva, Xiaokui Mo, Soledad Fernandez, and Peter J. Houghton

- 6730 **Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy**  
 Yvonne Kienast, Christian Klein, Werner Scheuer, Romi Raemsch, Erica Lorenzon, Dirk Bernicke, Frank Herting, Sidney Yu, Huynh Hung The, Laurent Martarello, Christian Gassner, Kay-Gunnar Stubenrauch, Kate Munro, Hellmut G. Augustin, and Markus Thomas
- 6741 **Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response**  
 Vanessa E. Zannella, Alan Dal Pra, Hala Muaddi, Trevor D. McKee, Shawn Stapleton, Jenna Sykes, Rachel Glicksman, Selim Chaib, Paul Zamiara, Michael Milosevic, Bradley G. Wouters, Robert G. Bristow, and Marianne Koritzinsky
- 6751 **Increased TGF- $\alpha$  as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells**  
 Teresa Troiani, Erika Martinelli, Stefania Napolitano, Donata Vitagliano, Loreta Pia Ciuffreda, Sara Costantino, Floriana Morgillo, Anna Capasso, Vincenzo Sforza, Anna Nappi, Raffaele De Palma, Elena D'Aiuto, Liberato Berrino, Roberto Bianco, and Fortunato Ciardiello
- 6766 **Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors**  
 Krupa J. Patel, Carol Lee, Qian Tan, and Ian F. Tannock
- 6777 **The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers *In Vitro* and *In Vivo***  
 Jih-Hsiang Lee, Kang-Seo Park, Anna Teresa Alberobello, Bhaskar Kallakury, Meng-Tzu Weng, Yisong Wang, and Giuseppe Giaccone
- 6787 **A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells**  
 Isabel Puig, Irene Chicote, Stephan P. Tenbaum, Oriol Arqués, José Raúl Herance, Juan D. Gispert, José Jimenez, Stefania Landolfi, Karina Caci, Helena Allende, Leire Mendizabal, Debora Moreno, Ramón Charco, Eloy Espín, Aleix Prat, Maria Elena Elez, Guillem Argilés, Ana Vivancos, Josep Tabernero, Santiago Rojas, and Héctor G. Palmer
- 6802 **Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis**  
 Ren Liu, Xiuqing Li, Wenming Gao, Yue Zhou, Shiuian Wey, Satyajit K. Mitra, Valery Krasnoperov, Dezheng Dong, Shuanglong Liu, Dan Li, Genyuan Zhu, Stan Louie, Peter S. Conti, Zibo Li, Amy S. Lee, and Parkash S. Gill
- IMAGING, DIAGNOSIS, PROGNOSIS**
- 6812 **Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma**  
 Preethi Reddy Marri, Lucy S. Hodge, Matthew J. Maurer, Steven C. Ziesmer, Susan L. Slager, Thomas M. Habermann, Brian K. Link, James R. Cerhan, Anne J. Novak, and Stephen M. Ansell
- 6820 **A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkins Lymphoma**  
 Arutselvan Natarajan, Benjamin J. Hackel, and Sanjiv Sam Gambhir
- 6830 **Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas**  
 Dario Garcia-Carracedo, Andrew T. Turk, Stuart A. Fine, Nathan Akhavan, Benjamin C. Tweel, Ramon Parsons, John A. Chabot, John D. Allendorf, Jeanine M. Genkinger, Helen E. Remotti, and Gloria H. Su
- 6842 **Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma**  
 Ernest Nadal, Guoan Chen, Marc Gallegos, Lin Lin, Daysha Ferrer-Torres, Anna Truini, Zhuwen Wang, Jules Lin, Rishindra M. Reddy, Roger Llatjos, Ignacio Escobar, Juan Moya, Andrew C. Chang, Felipe Cardenal, Gabriel Capellà, and David G. Beer

6853 **The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy**  
Sheng Chen, Yi-Zhou Jiang, Liang Huang, Ruo-Ji Zhou, Ke-Da Yu, Yin Liu, and Zhi-Ming Shao

## CANCER THERAPY: CLINICAL

6863 **Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis**  
Carlo Palmieri, John R. Fullarton, and Janet Brown

6873 **Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia**  
Robert J. Kreitman, Wyndham Wilson, Katherine R. Calvo, Evgeny Arons, Laura Roth, Jeffrey Sapolsky, Hong Zhou, Mark Raffeld, and Maryalice Stetler-Stevenson

6882 **Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma**  
Yasuhiro Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland, Jorge Romaguera, Larry W. Kwak, Barbara Pro, Silvana de Castro Faria, Sattva Neelapu, Nathan Fowler, Fredrick Hagemester, Jiexin Zhang, Shouhao Zhou, Lei Feng, and Anas Younes

6891 **Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer**  
A.J. Armstrong, M. Häggman, W.M. Stadler, J.R. Gingrich, V. Assikis, J. Polikoff, J.E. Damber, L. Belkoff, Ö. Nordle, G. Forsberg, M.A. Carducci, and R. Pili

6902 **Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates**  
Janelle M. Meyer, Kelly S. Perlewitz, James B. Hayden, Yee-Cheen Doung, Arthur Y. Hung, John T. Vetto, Rodney F. Pommier, Atiya Mansoor, Brooke R. Beckett, Alina Tudorica, Motomi Mori, Megan L. Holtorf, Aneela Afzal, William J. Woodward, Eve T. Rodler, Robin L. Jones, Wei Huang, and Christopher W. Ryan

## PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

6912 **Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors**  
David S. Shames, Kristi Elkins, Kimberly Walter, Thomas Holcomb, Pan Du, Dane Mohl, Yang Xiao, Thinh Pham, Peter M. Haverty, Bianca Liederer, Xiaorong Liang, Robert L. Yauch, Thomas O'Brien, Richard Bourgon, Hartmut Koeppen, and Lisa D. Belmont

6924 **The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer**  
Kevin Sharpe, Grant D. Stewart, Alan Mackay, Christophe Van Neste, Charlotte Rofe, Dan Berney, Irfan Kayani, Axel Bex, Elaine Wan, Fiach C. O'Mahony, Marie O'Donnell, Simon Chowdhury, Rukma Doshi, Colan Ho-Yen, Marco Gerlinger, Dawn Baker, Neil Smith, Barry Davies, Anju Sahdev, Ekaterini Boleti, Tim De Meyer, Wim Van Criekinge, Luis Beltran, Yong-Jie Lu, David J. Harrison, Andrew R. Reynolds, and Tom Powles

6935 **Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib**  
Jie Dai, Yan Kong, Lu Si, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Lili Mao, Siming Li, Bin Lian, Ruifeng Yang, Shujing Liu, Xiaowei Xu, and Jun Guo

6943 **Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy**  
Neil R. Smith, Dawn Baker, Matthew Farren, Aurelien Pommier, Ruth Swann, Xin Wang, Sunita Mistry, Karen McDavid, Jane Kendrew, Chris Womack, Stephen R. Wedge, and Simon T. Barry  
*See related article, p. 6647*

6957 **Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)**  
Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedy L. Kindler, Richard M. Goldberg, Alan P. Venook, and Herbert I. Hurwitz for the Alliance for Clinical Trials In Oncology

6967

**Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial**

George R. Blumenschein Jr, Pierre Saintigny, Suyu Liu, Edward S. Kim, Anne S. Tsao, Roy S. Herbst, Christine Alden, J. Jack Lee, Ximing Tang, David J. Stewart, Merrill S. Kies, Frank V. Fossella, Hai T. Tran, L. Mao, Marshall E. Hicks, Jeremy Erasmus Jr, Sanjay Gupta, Luc Girard, Michael Peyton, Lixia Diao, Jing Wang, Suzanne E. Davis, John D. Minna, Ignacio Wistuba, Waun K. Hong, John V. Heymach, and Scott M. Lippman

6976



**Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068**

Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodríguez, Marta Guzman, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao, Marie-Claire Wagle, Jenny Q. Wu, Matthew Wongchenko, Garret Hampton, Vanitha Ramakrishnan, Mark R. Lackner, Cristina Saura, Desamparados Roda, Andrés Cervantes, Josep Tabernero, Premal Patel, and José Baselga

6987

**Acknowledgment to Reviewers**


AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

**ABOUT THE COVER**

The cover shows drug distribution in a solid tumor derived from breast cancer cells in a mouse xenograft. Immunohistochemical staining shows enhanced doxorubicin distribution around functional blood vessels in mice pretreated with pantoprazole. For details, see the article by Patel and colleagues on page 6766 of this issue.



# Clinical Cancer Research

**19 (24)**

*Clin Cancer Res* 2013;19:6645-7013.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/19/24>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/19/24>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.